# Xeriant, Inc.: financial statements, quarterly XERI · OTC · CIK 1481504 · [Industrials](/sectors/industrials.md) · fiscal year ends Jun 30 Pages: [Overview](/companies/xeri.md) · [Financials](/companies/xeri/financials.md) · [Filings](/companies/xeri/filings.md) · [Insiders](/companies/xeri/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/xeri/financials.md?period=annual). ## Income statement | Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross profit | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Research and development | $k | [27.0](/filings/0001477932-24-007198.md) | [52.8](/filings/0001477932-25-001010.md) | [67.5](/filings/0001477932-25-003761.md) | [49.2 d](/filings/0001477932-25-007303.md) | [26.6](/filings/0001477932-25-008494.md) | [0.0](/filings/0001477932-26-000862.md) | [30.2](/filings/0001477932-26-003234.md) | [12.5 d](/filings/0001477932-26-005837.md) | [54.0](/filings/0001477932-25-008494.md) | [16.3](/filings/0001477932-26-000862.md) | [29.6](/filings/0001477932-26-003234.md) | [0.0 d](/filings/0001477932-26-005837.md) | | Selling, general and administrative | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating income | $k | [(319)](/filings/0001477932-24-007198.md) | [(340)](/filings/0001477932-25-001010.md) | [(353)](/filings/0001477932-25-003761.md) | [(894) d](/filings/0001477932-25-007303.md) | [(359)](/filings/0001477932-25-008494.md) | [(336)](/filings/0001477932-26-000862.md) | [(459)](/filings/0001477932-26-003234.md) | [(212) d](/filings/0001477932-26-005837.md) | [(304)](/filings/0001477932-25-008494.md) | [(231)](/filings/0001477932-26-000862.md) | [(351)](/filings/0001477932-26-003234.md) | [(172) d](/filings/0001477932-26-005837.md) | | Interest expense | $k | [20.7](/filings/0001477932-24-007198.md) | [847](/filings/0001477932-25-001010.md) | [28.6](/filings/0001477932-25-003761.md) | [288 d](/filings/0001477932-25-007303.md) | [61.6](/filings/0001477932-25-008494.md) | [51.4](/filings/0001477932-26-000862.md) | [66.2](/filings/0001477932-26-003234.md) | [46.4 d](/filings/0001477932-26-005837.md) | [44.8](/filings/0001477932-25-008494.md) | [35.8](/filings/0001477932-26-000862.md) | [45.6](/filings/0001477932-26-003234.md) | [(57.7) d](/filings/0001477932-26-005837.md) | | Income tax | $k | [0.0](/filings/0001477932-24-007198.md) | [0.0](/filings/0001477932-25-001010.md) | [0.0](/filings/0001477932-25-003761.md) | [0.0 d](/filings/0001477932-25-007303.md) | [0.0](/filings/0001477932-25-008494.md) | [0.0](/filings/0001477932-26-000862.md) | [0.0](/filings/0001477932-26-003234.md) | [0.0 d](/filings/0001477932-26-005837.md) | [125](/filings/0001477932-25-008494.md) | [(15.9)](/filings/0001477932-26-000862.md) | [(24.2)](/filings/0001477932-26-003234.md) | [(68.6) d](/filings/0001477932-26-005837.md) | | Net income | $k | [(342)](/filings/0001477932-24-007198.md) | [(1,199)](/filings/0001477932-25-001010.md) | [(376)](/filings/0001477932-25-003761.md) | [(1,194) d](/filings/0001477932-25-007303.md) | [(372)](/filings/0001477932-26-000862.md) | [(417)](/filings/0001477932-26-000862.md) | [(530)](/filings/0001477932-26-003234.md) | [(327) d](/filings/0001477932-26-005837.md) | [2,226](/filings/0001477932-26-000862.md) | [(298)](/filings/0001477932-26-000862.md) | [(419)](/filings/0001477932-26-003234.md) | [(1,117) d](/filings/0001477932-26-005837.md) | | Diluted EPS | $ per share | not reported | [0.00](/filings/0001477932-25-001010.md) | [0.00](/filings/0001477932-25-003761.md) | not reported | [0.00](/filings/0001477932-25-008494.md) | [0.00](/filings/0001477932-26-000862.md) | [0.00](/filings/0001477932-26-003234.md) | not reported | [0.00](/filings/0001477932-25-008494.md) | [0.00](/filings/0001477932-26-000862.md) | [0.00](/filings/0001477932-26-003234.md) | not reported | | Basic EPS | $ per share | not reported | not reported | not reported | not reported | [0.00](/filings/0001477932-25-008494.md) | [0.00](/filings/0001477932-26-000862.md) | [0.00](/filings/0001477932-26-003234.md) | not reported | [0.00](/filings/0001477932-25-008494.md) | [0.00](/filings/0001477932-26-000862.md) | [0.00](/filings/0001477932-26-003234.md) | not reported | - Revenue: not reported - Gross profit: not reported - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: not reported - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Current assets | $k | [168](/filings/0001477932-23-008302.md) | [53.4](/filings/0001477932-24-000713.md) | [389](/filings/0001477932-24-002829.md) | [664](/filings/0001477932-25-007303.md) | [320](/filings/0001477932-24-007198.md) | [269](/filings/0001477932-25-001010.md) | [61.9](/filings/0001477932-25-003761.md) | [56.7](/filings/0001477932-26-005837.md) | [61.7](/filings/0001477932-25-008494.md) | [94.9](/filings/0001477932-26-000862.md) | [33.8](/filings/0001477932-26-003234.md) | [91.2](/filings/0001477932-26-005837.md) | | Total assets | $k | [257](/filings/0001477932-23-008302.md) | [129](/filings/0001477932-24-000713.md) | [452](/filings/0001477932-24-002829.md) | [713](/filings/0001477932-25-007303.md) | [355](/filings/0001477932-24-007198.md) | [277](/filings/0001477932-25-001010.md) | [73.2](/filings/0001477932-25-003761.md) | [68.2](/filings/0001477932-26-005837.md) | [71.7](/filings/0001477932-25-008494.md) | [103](/filings/0001477932-26-000862.md) | [43.8](/filings/0001477932-26-003234.md) | [99.5](/filings/0001477932-26-005837.md) | | Current liabilities | $k | [7,132](/filings/0001477932-23-008302.md) | [7,942](/filings/0001477932-24-000713.md) | [8,617](/filings/0001477932-24-002829.md) | [9,325](/filings/0001477932-25-007303.md) | not reported | not reported | [8,660](/filings/0001477932-25-003761.md) | [8,766](/filings/0001477932-26-005837.md) | [5,772](/filings/0001477932-25-008494.md) | [5,740](/filings/0001477932-26-000862.md) | [5,839](/filings/0001477932-26-003234.md) | [4,989](/filings/0001477932-26-005837.md) | | Total liabilities | $k | [7,153](/filings/0001477932-23-008302.md) | [7,977](/filings/0001477932-24-000713.md) | [8,617](/filings/0001477932-24-002829.md) | [9,325](/filings/0001477932-25-007303.md) | [8,852](/filings/0001477932-24-007198.md) | [8,966](/filings/0001477932-25-001010.md) | [8,664](/filings/0001477932-25-003761.md) | [8,769](/filings/0001477932-26-005837.md) | [5,774](/filings/0001477932-25-008494.md) | [5,740](/filings/0001477932-26-000862.md) | [5,839](/filings/0001477932-26-003234.md) | [4,989](/filings/0001477932-26-005837.md) | | Long-term debt | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Shareholders' equity | $k | [(6,896)](/filings/0001477932-24-002829.md) | [(7,848)](/filings/0001477932-24-002829.md) | [(8,165)](/filings/0001477932-24-002829.md) | [(5,753)](/filings/0001477932-25-007303.md) | [(5,630)](/filings/0001477932-24-007198.md) | [(5,815)](/filings/0001477932-25-001010.md) | [(5,714)](/filings/0001477932-25-003761.md) | [(5,823)](/filings/0001477932-26-005837.md) | [(2,825)](/filings/0001477932-25-008494.md) | [(2,760)](/filings/0001477932-26-000862.md) | [(2,918)](/filings/0001477932-26-003234.md) | [(2,012)](/filings/0001477932-26-005837.md) | - Cash and equivalents: not reported - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: not reported - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $k | [(308)](/filings/0001477932-24-007198.md) | [(336) d](/filings/0001477932-25-001010.md) | [(415) d](/filings/0001477932-25-003761.md) | [(370) d](/filings/0001477932-25-007303.md) | [(353)](/filings/0001477932-25-008494.md) | [(398) d](/filings/0001477932-26-000862.md) | [(366) d](/filings/0001477932-26-003234.md) | [(172) d](/filings/0001477932-26-005837.md) | [(178)](/filings/0001477932-25-008494.md) | [(206) d](/filings/0001477932-26-000862.md) | [(224) d](/filings/0001477932-26-003234.md) | [(184) d](/filings/0001477932-26-005837.md) | | Capital expenditure | $k | [0.0](/filings/0001477932-23-008302.md) | [0.0 d](/filings/0001477932-24-000713.md) | [0.0 d](/filings/0001477932-24-002829.md) | [0.0 d](/filings/0001477932-25-007303.md) | not reported | not reported | not reported | [1.8 d](/filings/0001477932-26-005837.md) | not reported | not reported | not reported | [0.0 d](/filings/0001477932-26-005837.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment ## Shares | Line item | Unit | Q2 FY2018 (2017-12-31) | Q3 FY2018 (2018-03-31) | Q1 FY2022 (2021-09-30) | Q1 FY2023 (2022-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [69.6](/filings/0001477932-19-003699.md) | [69.6](/filings/0001477932-19-004160.md) | [225](/filings/0001477932-22-008809.md) | [362](/filings/0001477932-22-008809.md) | [423](/filings/0001477932-25-001010.md) | [449](/filings/0001477932-25-003761.md) | [548](/filings/0001477932-25-008494.md) | [596](/filings/0001477932-26-000862.md) | [655](/filings/0001477932-26-003234.md) | [2,367](/filings/0001477932-25-008494.md) | [780](/filings/0001477932-26-000862.md) | [882](/filings/0001477932-26-003234.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 1,086,360,294 at 2026-09-25, from the cover of the [10-K filed 2026-09-28](/filings/0001477932-26-005837.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.